[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fb9PNW72n8n4kKHjWXvNOxHiAh7NkexVF-oNiHEPjMBw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Federal University of Rio Grande do Sul",[4],118,false,11,1,23589,0,100,[14,17,19,21,24,26,29,31],{"name":15,"count":16},"Bipolar Disorder",5,{"name":18,"count":16},"Aging",{"name":20,"count":16},"Parkinson Disease",{"name":22,"count":23},"Gingival Recession",4,{"name":25,"count":23},"Obesity",{"name":27,"count":28},"Wounds and Injuries",3,{"name":30,"count":28},"Periodontitis",{"name":32,"count":28},"Diabetes Mellitus, Type 2",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,82,104,131,168,186,204,228,256,282,300,318,344,362,388,414,432,465,493,519,537,563,588],{"intervention":43,"totalTrials":44,"cells":45},"sertraline",2,{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":50,"PHASE3":52,"PHASE4":54,"NA":80},{"trials":47,"activeCount":11},[],{"trials":49,"activeCount":11},[],{"trials":51,"activeCount":11},[],{"trials":53,"activeCount":11},[],{"trials":55,"activeCount":11},[56,70],{"nctId":57,"briefTitle":58,"status":59,"phases":60,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":67},"NCT02901249","Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder","COMPLETED",[39],"2014-11","2015-09","2010-05",68,[66],"Depression",[43,68,69],"Nortriptyline","Lithium",{"nctId":71,"briefTitle":72,"status":59,"phases":73,"primaryCompletion":61,"completion":62,"start":63,"enrollment":74,"conditions":75,"interventions":76},"NCT02918097","Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode",[39],78,[15],[77,78,68,79],"Lithium Carbonate","Sertraline","Risperidone",{"trials":81,"activeCount":11},[],{"intervention":68,"totalTrials":44,"cells":83},{"EARLY_PHASE1":84,"PHASE1":86,"PHASE2":88,"PHASE3":90,"PHASE4":92,"NA":102},{"trials":85,"activeCount":11},[],{"trials":87,"activeCount":11},[],{"trials":89,"activeCount":11},[],{"trials":91,"activeCount":11},[],{"trials":93,"activeCount":11},[94,98],{"nctId":57,"briefTitle":58,"status":59,"phases":95,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":96,"interventions":97},[39],[66],[43,68,69],{"nctId":71,"briefTitle":72,"status":59,"phases":99,"primaryCompletion":61,"completion":62,"start":63,"enrollment":74,"conditions":100,"interventions":101},[39],[15],[77,78,68,79],{"trials":103,"activeCount":11},[],{"intervention":69,"totalTrials":44,"cells":105},{"EARLY_PHASE1":106,"PHASE1":108,"PHASE2":110,"PHASE3":112,"PHASE4":114,"NA":129},{"trials":107,"activeCount":11},[],{"trials":109,"activeCount":11},[],{"trials":111,"activeCount":11},[],{"trials":113,"activeCount":11},[],{"trials":115,"activeCount":11},[116,120],{"nctId":57,"briefTitle":58,"status":59,"phases":117,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":118,"interventions":119},[39],[66],[43,68,69],{"nctId":121,"briefTitle":122,"status":59,"phases":123,"primaryCompletion":61,"completion":62,"start":63,"enrollment":124,"conditions":125,"interventions":126},"NCT02870283","Cost- Effectiveness and Quality of Life Assessment in Mood Disorder",[39],107,[15],[69,127,128],"Valproic Acid","Carbamazepine",{"trials":130,"activeCount":11},[],{"intervention":132,"totalTrials":44,"cells":133},"Methylphenidate",{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":166},{"trials":135,"activeCount":11},[],{"trials":137,"activeCount":11},[],{"trials":139,"activeCount":11},[],{"trials":141,"activeCount":11},[],{"trials":143,"activeCount":11},[144,155],{"nctId":145,"briefTitle":146,"status":59,"phases":147,"primaryCompletion":148,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":154},"NCT00773916","The Role of Adverse Environment Factors, Family Functioning and Parental Psychopathology in the Response to Treatment With Methylphenidate in Children and Adolescents With Attention Deficit\u002FHyperactivity Disorder",[39],"2008-07","2009-07","2006-03",130,[153],"Attention Deficit Disorder With Hyperactivity",[132],{"nctId":156,"briefTitle":157,"status":158,"phases":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":165},"NCT00536419","Impact of Attention Deficit\u002FHyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents","UNKNOWN",[39],"2008-09","2007-09",53,[164],"Attention Deficit Hyperactivity Disorder",[132],{"trials":167,"activeCount":11},[],{"intervention":127,"totalTrials":9,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":184},{"trials":171,"activeCount":11},[],{"trials":173,"activeCount":11},[],{"trials":175,"activeCount":11},[],{"trials":177,"activeCount":11},[],{"trials":179,"activeCount":11},[180],{"nctId":121,"briefTitle":122,"status":59,"phases":181,"primaryCompletion":61,"completion":62,"start":63,"enrollment":124,"conditions":182,"interventions":183},[39],[15],[69,127,128],{"trials":185,"activeCount":11},[],{"intervention":128,"totalTrials":9,"cells":187},{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":196,"NA":202},{"trials":189,"activeCount":11},[],{"trials":191,"activeCount":11},[],{"trials":193,"activeCount":11},[],{"trials":195,"activeCount":11},[],{"trials":197,"activeCount":11},[198],{"nctId":121,"briefTitle":122,"status":59,"phases":199,"primaryCompletion":61,"completion":62,"start":63,"enrollment":124,"conditions":200,"interventions":201},[39],[15],[69,127,128],{"trials":203,"activeCount":11},[],{"intervention":205,"totalTrials":9,"cells":206},"Psychopharmacotherapy",{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":215,"NA":226},{"trials":208,"activeCount":11},[],{"trials":210,"activeCount":11},[],{"trials":212,"activeCount":11},[],{"trials":214,"activeCount":11},[],{"trials":216,"activeCount":11},[217],{"nctId":218,"briefTitle":219,"status":158,"phases":220,"primaryCompletion":221,"completion":61,"start":222,"enrollment":223,"conditions":224,"interventions":225},"NCT01000402","Juvenile Bipolar Disorder Outpatient Program",[39],"2012-10","2008-02",150,[15,153],[205],{"trials":227,"activeCount":11},[],{"intervention":229,"totalTrials":9,"cells":230},"N-acetylcysteine",{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":254},{"trials":232,"activeCount":11},[],{"trials":234,"activeCount":11},[],{"trials":236,"activeCount":11},[],{"trials":238,"activeCount":11},[],{"trials":240,"activeCount":11},[241],{"nctId":242,"briefTitle":243,"status":59,"phases":244,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":253},"NCT01501110","Effects of N-acetylcysteine on Low T3 Syndrome",[39],"2013-07","2013-11","2011-11",83,[250,251,252],"Acute Myocardial Infarction","Euthyroid Sick Syndrome","Ischemic Heart Disease",[229],{"trials":255,"activeCount":11},[],{"intervention":257,"totalTrials":9,"cells":258},"Ezetimibe",{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":280},{"trials":260,"activeCount":11},[],{"trials":262,"activeCount":11},[],{"trials":264,"activeCount":11},[],{"trials":266,"activeCount":11},[],{"trials":268,"activeCount":11},[269],{"nctId":270,"briefTitle":271,"status":59,"phases":272,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":278},"NCT02234544","Effect of an Inhibitor of Cholesterol Absorption on Vitamin D Levels",[39],"2015-04","2014-10",52,[277],"Vitamin D Deficiency",[257,279],"Cholecalciferol",{"trials":281,"activeCount":11},[],{"intervention":279,"totalTrials":9,"cells":283},{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":292,"NA":298},{"trials":285,"activeCount":11},[],{"trials":287,"activeCount":11},[],{"trials":289,"activeCount":11},[],{"trials":291,"activeCount":11},[],{"trials":293,"activeCount":11},[294],{"nctId":270,"briefTitle":271,"status":59,"phases":295,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":296,"interventions":297},[39],[277],[257,279],{"trials":299,"activeCount":11},[],{"intervention":77,"totalTrials":9,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":310,"NA":316},{"trials":303,"activeCount":11},[],{"trials":305,"activeCount":11},[],{"trials":307,"activeCount":11},[],{"trials":309,"activeCount":11},[],{"trials":311,"activeCount":11},[312],{"nctId":71,"briefTitle":72,"status":59,"phases":313,"primaryCompletion":61,"completion":62,"start":63,"enrollment":74,"conditions":314,"interventions":315},[39],[15],[77,78,68,79],{"trials":317,"activeCount":11},[],{"intervention":319,"totalTrials":9,"cells":320},"0.12% Clorhexidine with alcohol",{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":340,"NA":342},{"trials":322,"activeCount":11},[],{"trials":324,"activeCount":11},[],{"trials":326,"activeCount":11},[],{"trials":328,"activeCount":11},[329],{"nctId":330,"briefTitle":331,"status":59,"phases":332,"primaryCompletion":333,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":338},"NCT02656251","Efficacy of Two Chlorhexidine Solutions to Control the Initial Subgingival Biofilm Formation",[38],"2015-12","2015-07",35,[337],"Dental Plaque",[319,339],"0.12% Clorhexidine without alcohol",{"trials":341,"activeCount":11},[],{"trials":343,"activeCount":11},[],{"intervention":339,"totalTrials":9,"cells":345},{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":352,"PHASE4":358,"NA":360},{"trials":347,"activeCount":11},[],{"trials":349,"activeCount":11},[],{"trials":351,"activeCount":11},[],{"trials":353,"activeCount":11},[354],{"nctId":330,"briefTitle":331,"status":59,"phases":355,"primaryCompletion":333,"completion":333,"start":334,"enrollment":335,"conditions":356,"interventions":357},[38],[337],[319,339],{"trials":359,"activeCount":11},[],{"trials":361,"activeCount":11},[],{"intervention":363,"totalTrials":9,"cells":364},"resveratrol",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":382,"PHASE4":384,"NA":386},{"trials":366,"activeCount":11},[],{"trials":368,"activeCount":11},[],{"trials":370,"activeCount":11},[371],{"nctId":372,"briefTitle":373,"status":59,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},"NCT02062190","Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia",[37],"2015-01","2015-05","2014-03",19,[380],"Schizophrenia",[363],{"trials":383,"activeCount":11},[],{"trials":385,"activeCount":11},[],{"trials":387,"activeCount":11},[],{"intervention":389,"totalTrials":9,"cells":390},"Oral Nicotinamide",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":412},{"trials":392,"activeCount":11},[],{"trials":394,"activeCount":11},[395],{"nctId":396,"briefTitle":397,"status":59,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":404},"NCT07049068","Comparison of Nicotinamide Treatments for Actinic Keratosis",[36],"2024-11-30","2022-02-01",74,[403],"Actinic Keratoses",[389,405],"topical nicotinamide",{"trials":407,"activeCount":11},[],{"trials":409,"activeCount":11},[],{"trials":411,"activeCount":11},[],{"trials":413,"activeCount":11},[],{"intervention":405,"totalTrials":9,"cells":415},{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":430},{"trials":417,"activeCount":11},[],{"trials":419,"activeCount":11},[420],{"nctId":396,"briefTitle":397,"status":59,"phases":421,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":422,"interventions":423},[36],[403],[389,405],{"trials":425,"activeCount":11},[],{"trials":427,"activeCount":11},[],{"trials":429,"activeCount":11},[],{"trials":431,"activeCount":11},[],{"intervention":433,"totalTrials":44,"cells":434},"Aripiprazole",{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":455},{"trials":436,"activeCount":11},[],{"trials":438,"activeCount":11},[],{"trials":440,"activeCount":11},[],{"trials":442,"activeCount":11},[],{"trials":444,"activeCount":11},[445],{"nctId":446,"briefTitle":447,"status":59,"phases":448,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":454},"NCT00305370","Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD",[39],"2008-01","2008-03","2005-08",20,[15,164],[433],{"trials":456,"activeCount":11},[457],{"nctId":458,"briefTitle":459,"status":59,"phases":460,"primaryCompletion":449,"completion":222,"start":461,"enrollment":462,"conditions":463,"interventions":464},"NCT00116259","Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD)",[40],"2005-03",50,[15,164],[433],{"intervention":79,"totalTrials":44,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":481},{"trials":468,"activeCount":11},[],{"trials":470,"activeCount":11},[],{"trials":472,"activeCount":11},[],{"trials":474,"activeCount":11},[],{"trials":476,"activeCount":11},[477],{"nctId":71,"briefTitle":72,"status":59,"phases":478,"primaryCompletion":61,"completion":62,"start":63,"enrollment":74,"conditions":479,"interventions":480},[39],[15],[77,78,68,79],{"trials":482,"activeCount":11},[483],{"nctId":484,"briefTitle":485,"status":158,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":452,"conditions":490,"interventions":492},"NCT00825552","Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation",[40],"2010-01","2010-11","2009-01",[491],"Severe Mood Dysregulation",[79],{"intervention":494,"totalTrials":9,"cells":495},"Fixed-dose oral tablet of codeine\u002F acetaminophen every 4 hours for 3 days",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":504,"NA":506},{"trials":497,"activeCount":11},[],{"trials":499,"activeCount":11},[],{"trials":501,"activeCount":11},[],{"trials":503,"activeCount":11},[],{"trials":505,"activeCount":11},[],{"trials":507,"activeCount":11},[508],{"nctId":509,"briefTitle":510,"status":59,"phases":511,"primaryCompletion":512,"completion":273,"start":513,"enrollment":514,"conditions":515,"interventions":517},"NCT02750696","Comparison of Two Combinations of Opioid and Non-opioid Analgesics for Acute Periradicular Abscess",[40],"2014-12","2013-04",27,[516],"Periapical Abscess",[494,518],"Fixed-dose oral tablet of tramadol\u002F acetaminophen every 4 hours for 3 days",{"intervention":518,"totalTrials":9,"cells":520},{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":522,"activeCount":11},[],{"trials":524,"activeCount":11},[],{"trials":526,"activeCount":11},[],{"trials":528,"activeCount":11},[],{"trials":530,"activeCount":11},[],{"trials":532,"activeCount":11},[533],{"nctId":509,"briefTitle":510,"status":59,"phases":534,"primaryCompletion":512,"completion":273,"start":513,"enrollment":514,"conditions":535,"interventions":536},[40],[516],[494,518],{"intervention":538,"totalTrials":9,"cells":539},"Metronidazole",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":548,"NA":550},{"trials":541,"activeCount":11},[],{"trials":543,"activeCount":11},[],{"trials":545,"activeCount":11},[],{"trials":547,"activeCount":11},[],{"trials":549,"activeCount":11},[],{"trials":551,"activeCount":11},[552],{"nctId":553,"briefTitle":554,"status":158,"phases":555,"primaryCompletion":556,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},"NCT01405365","The Impact of Obesity on Nonsurgical Periodontal Therapy",[40],"2011-12","2012-12","2009-08",96,[30,561,25],"Periodontal Diseases",[538],{"intervention":564,"totalTrials":9,"cells":565},"oral contraceptive pill",{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":567,"activeCount":11},[],{"trials":569,"activeCount":11},[],{"trials":571,"activeCount":11},[],{"trials":573,"activeCount":11},[],{"trials":575,"activeCount":11},[],{"trials":577,"activeCount":11},[578],{"nctId":579,"briefTitle":580,"status":59,"phases":581,"primaryCompletion":449,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":587},"NCT01372293","71A\u002FG HSD17B5 SNP and Effects of Oral Contraceptive Pill in PCOS Women",[40],"2010-12","2005-01",49,[586],"Polycystic Ovary Syndrome",[564],{"intervention":589,"totalTrials":9,"cells":590},"Prostaglandin analogue eye drops",{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":599,"NA":601},{"trials":592,"activeCount":11},[],{"trials":594,"activeCount":11},[],{"trials":596,"activeCount":11},[],{"trials":598,"activeCount":11},[],{"trials":600,"activeCount":11},[],{"trials":602,"activeCount":11},[603],{"nctId":604,"briefTitle":605,"status":158,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":613},"NCT05241938","PSLT Compared to Prostaglandin Analogue Eye Drops",[40],"2022-12-20","2021-09-01",75,[611,612],"Open Angle Glaucoma","Ocular Hypertension",[589]]